Abstract
Malaria sexual stage and mosquito transmission-blocking vaccines (SSM-TBV) have recently gained prominence as a necessary tool for malaria eradication. SSM-TBVs are unique in that, with the exception of parasite gametocyte antigens, they primarily target parasite or mosquito midgut surface antigens expressed only inside the mosquito. As such, the primary perceived limitation of SSM-TBVs is that the absence of natural boosting following immunization will limit its efficacy, since the antigens are never presented to the human immune system. An ideal, safe SSM-TBV formulation must overcome this limitation. We provide a focused evaluation of relevant nano-/microparticle technologies that can be applied toward the development of leading SSM-TBV candidates, and data from a proof-of-concept study demonstrating that a single inoculation and controlled release of antigen in mice, can elicit long-lasting protective antibody titers. We conclude by identifying the remaining critical gaps in knowledge and opportunities for moving SSM-TBVs to the field.
Keywords: Antigen, controlled release, immunity, malaria, midgut, mosquito, nanotechnology, natural boosting, sexual stages, transmission-blocking vaccine
Current Molecular Medicine
Title:Single-Dose Microparticle Delivery of a Malaria Transmission- Blocking Vaccine Elicits a Long-Lasting Functional Antibody Response
Volume: 13 Issue: 4
Author(s): R.R. Dinglasan, J.S. Armistead, J.F. Nyland, X. Jiang and H.Q. Mao
Affiliation:
Keywords: Antigen, controlled release, immunity, malaria, midgut, mosquito, nanotechnology, natural boosting, sexual stages, transmission-blocking vaccine
Abstract: Malaria sexual stage and mosquito transmission-blocking vaccines (SSM-TBV) have recently gained prominence as a necessary tool for malaria eradication. SSM-TBVs are unique in that, with the exception of parasite gametocyte antigens, they primarily target parasite or mosquito midgut surface antigens expressed only inside the mosquito. As such, the primary perceived limitation of SSM-TBVs is that the absence of natural boosting following immunization will limit its efficacy, since the antigens are never presented to the human immune system. An ideal, safe SSM-TBV formulation must overcome this limitation. We provide a focused evaluation of relevant nano-/microparticle technologies that can be applied toward the development of leading SSM-TBV candidates, and data from a proof-of-concept study demonstrating that a single inoculation and controlled release of antigen in mice, can elicit long-lasting protective antibody titers. We conclude by identifying the remaining critical gaps in knowledge and opportunities for moving SSM-TBVs to the field.
Export Options
About this article
Cite this article as:
Dinglasan R.R., Armistead J.S., Nyland J.F., Jiang X. and Mao H.Q., Single-Dose Microparticle Delivery of a Malaria Transmission- Blocking Vaccine Elicits a Long-Lasting Functional Antibody Response, Current Molecular Medicine 2013; 13 (4) . https://dx.doi.org/10.2174/1566524011313040002
DOI https://dx.doi.org/10.2174/1566524011313040002 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Inhaled Corticosteroids In Treatment of Cystic Fibrosis
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Pomegranin, An Antifungal Peptide from Pomegranate Peels
Protein & Peptide Letters The Relationships between the Transforming Growth Factor-β 1, Age and the Ultrasound Parameters of Arterial Wall
Vascular Disease Prevention (Discontinued) Clinical Studies Using Biological and Synthetic Materials for Meniscus Replacement
Current Stem Cell Research & Therapy Recent Advances in the Development of Selective CB2 Agonists as Promising Anti-Inflammatory Agents
Current Medicinal Chemistry Apoptosis: A Potential Therapeutic Target for Retinal Degenerations
Current Neurovascular Research Mechanisms of Esophageal Protection, Gastroprotection and Ulcer Healing by Melatonin. Implications for the Therapeutic use of Melatonin in Gastroesophageal Reflux Disease (GERD) and Peptic Ulcer Disease
Current Pharmaceutical Design Hydroxyproline: A Potential Biochemical Marker and Its Role in the Pathogenesis of Different Diseases
Current Protein & Peptide Science Enhanced Gene Delivery and/or Efficacy by Functional Peptide and Protein
Current Topics in Medicinal Chemistry Interleukin-10 in the Vasculature: Pathophysiological Implications
Current Vascular Pharmacology Patent Selections:
Recent Patents on Nanotechnology Gene Therapy for Rheumatoid Arthritis: Recent Advances
Current Gene Therapy Jak2 and Reactive Oxygen Species: A Complex Relationship
Current Chemical Biology Cardiovascular Adverse Effects of Anti-Inflammatory Drugs
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Transport of Nucleoside Analogs Across the Plasma Membrane: A Clue to Understanding Drug-Induced Cytotoxicity
Current Drug Metabolism Multitarget Cannabinoids as Novel Strategy for Alzheimer Disease
Current Alzheimer Research Animal Venom Peptides: Potential for New Antimicrobial Agents
Current Topics in Medicinal Chemistry Regulation of the DNA Damage Response to DSBs by Post-Translational Modifications
Current Genomics Early Aged T-Cells in Immune-Mediated Diseases
Current Immunology Reviews (Discontinued) Patent Selections:
Recent Patents on Inflammation & Allergy Drug Discovery